The Biden administration plans to stop paying for COVID vaccines and will begin shifting costs toward the marketplace, according to a Thursday report from The Wall Street Journal.

The Department of Health and Human Services will hold a planning session at the end of the month with pharmaceutical companies and state health departments to chart the transition, according to the outlet. The move could result in higher profits for Pfizer and Moderna, which, along with other pharmaceutical companies, have earned more than $79 billion in global sales from COVID shots and treatments.

“We’ve known at some point we’d need to move over into the commercial market, and we’re approaching that time now,” Health and Human Services Assistant Secretary Dawn O’Connell told The Journal. “We don’t want to do it by fiat.”

Because a shift to the marketplace will lead to insurers negotiating with manufacturers to determine prices, costs for COVID treatments will likely increase as insurance premiums rise. Meanwhile, roughly 31.6 million Americans do not have health insurance, according to the Centers for Disease Control and Prevention.

The White House requested $22.5 billion in new funds for COVID treatments in March. Office of Management and Budget Acting Director Shalanda Young contended in a letter to House Speaker Nancy Pelosi (D-CA) that a lack of funding would leave the nation “unequipped to deal with a future surge,” especially with regard to variant-specific booster shots.